Humasis Co. Ltd (205470) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Humasis Co. Ltd (205470) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.98 Billion ≈ $6.08 Million USD) by net assets (₩248.94 Billion ≈ $168.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Humasis Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Humasis Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read total liabilities of Humasis Co. Ltd for a breakdown of total debt and financial obligations.
Humasis Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humasis Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Agripure Holdings Public Company Limited
BK:APURE
|
-0.003x |
|
S Chand And Company Limited
NSE:SCHAND
|
-0.061x |
|
IZEA Inc
NASDAQ:IZEA
|
0.024x |
|
Thorney Opportunities Ltd
AU:TOP
|
-0.036x |
|
Entertainment Network (India) Limited
NSE:ENIL
|
-0.016x |
|
Hongli Group Inc. Ordinary Shares
NASDAQ:HLP
|
-0.005x |
|
Peninsula Land Limited
NSE:PENINLAND
|
0.030x |
|
Linz Textil Holding AG
VI:LTH
|
0.059x |
Annual Cash Flow Conversion Efficiency for Humasis Co. Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Humasis Co. Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Humasis Co. Ltd stock valuation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩229.26 Billion ≈ $155.37 Million |
₩30.37 Billion ≈ $20.58 Million |
0.132x | +168.60% |
| 2023-12-31 | ₩287.33 Billion ≈ $194.72 Million |
₩-55.48 Billion ≈ $-37.60 Million |
-0.193x | -133.05% |
| 2022-12-31 | ₩346.73 Billion ≈ $234.98 Million |
₩202.60 Billion ≈ $137.30 Million |
0.584x | -42.43% |
| 2021-12-31 | ₩202.01 Billion ≈ $136.90 Million |
₩205.02 Billion ≈ $138.94 Million |
1.015x | +246.69% |
| 2020-12-31 | ₩48.84 Billion ≈ $33.10 Million |
₩14.30 Billion ≈ $9.69 Million |
0.293x | +472.45% |
| 2019-12-31 | ₩15.24 Billion ≈ $10.33 Million |
₩779.58 Million ≈ $528.31K |
0.051x | +210.38% |
| 2018-12-31 | ₩16.13 Billion ≈ $10.93 Million |
₩-747.08 Million ≈ $-506.29K |
-0.046x | +75.66% |
| 2017-12-31 | ₩15.60 Billion ≈ $10.57 Million |
₩-2.97 Billion ≈ $-2.01 Million |
-0.190x | -1468.41% |
| 2016-12-31 | ₩10.86 Billion ≈ $7.36 Million |
₩151.11 Million ≈ $102.40K |
0.014x | -- |
About Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more